These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 35901996)

  • 21. A Cost-Effectiveness Analysis of Intravitreal Aflibercept for the Prevention of Progressive Diabetic Retinopathy.
    Patel NA; Yannuzzi NA; Lin J; Smiddy WE
    Ophthalmol Retina; 2022 Mar; 6(3):213-218. PubMed ID: 34547529
    [TBL] [Abstract][Full Text] [Related]  

  • 22. INTRAVITREAL INJECTIONS OF ZIV-AFLIBERCEPT FOR DIABETIC MACULAR EDEMA: A Pilot Study.
    Andrade GC; Dias JR; Maia A; Farah ME; Meyer CH; Rodrigues EB
    Retina; 2016 Sep; 36(9):1640-5. PubMed ID: 26991646
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systemic and Ocular Adverse Events with Intravitreal Anti-VEGF Therapy Used in the Treatment of Diabetic Retinopathy: a Review.
    Zehden JA; Mortensen XM; Reddy A; Zhang AY
    Curr Diab Rep; 2022 Oct; 22(10):525-536. PubMed ID: 36053385
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema Treatment: Analysis From the Diabetic Retinopathy Clinical Research Network Comparative Effectiveness Trial.
    Ross EL; Hutton DW; Stein JD; Bressler NM; Jampol LM; Glassman AR;
    JAMA Ophthalmol; 2016 Aug; 134(8):888-96. PubMed ID: 27280850
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intravitreal Aflibercept Injection in Diabetic Macular Edema Patients with and without Prior Anti-Vascular Endothelial Growth Factor Treatment: Outcomes from the Phase 3 Program.
    Do DV; Nguyen QD; Vitti R; Berliner AJ; Gibson A; Saroj N; Soo Y; Boyer DS
    Ophthalmology; 2016 Apr; 123(4):850-7. PubMed ID: 26832658
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-consequence analysis of extended loading dose of anti-VEGF treatment in diabetic macular edema patients.
    Ruiz-Moreno JM; de Andrés-Nogales F; Oyagüez I
    BMC Ophthalmol; 2020 Sep; 20(1):371. PubMed ID: 32943041
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of intravitreal anti-VEGF therapy in diabetic retinopathy: what we have learned and what should we learn further?
    Uludag G; Hassan M; Matsumiya W; Pham BH; Chea S; Trong Tuong Than N; Doan HL; Akhavanrezayat A; Halim MS; Do DV; Nguyen QD
    Expert Opin Biol Ther; 2022 Oct; 22(10):1275-1291. PubMed ID: 35818801
    [TBL] [Abstract][Full Text] [Related]  

  • 28. COMPARISON OF INTRAVITREAL DEXAMETHASONE IMPLANT AND AFLIBERCEPT IN PATIENTS WITH TREATMENT-NAIVE DIABETIC MACULAR EDEMA WITH SEROUS RETINAL DETACHMENT.
    Ozsaygili C; Duru N
    Retina; 2020 Jun; 40(6):1044-1052. PubMed ID: 30950970
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recent clinically relevant highlights from the Diabetic Retinopathy Clinical Research Network.
    Krick TW; Bressler NM
    Curr Opin Ophthalmol; 2018 May; 29(3):199-205. PubMed ID: 29528861
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Four-Year Visual Outcomes in the Protocol W Randomized Trial of Intravitreous Aflibercept for Prevention of Vision-Threatening Complications of Diabetic Retinopathy.
    Maturi RK; Glassman AR; Josic K; Baker CW; Gerstenblith AT; Jampol LM; Meleth A; Martin DF; Melia M; Punjabi OS; Rofagha S; Salehi-Had H; Stockdale CR; Sun JK;
    JAMA; 2023 Feb; 329(5):376-385. PubMed ID: 36749332
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravitreal dexamethasone insert in diabetic macular edema super-refractory to anti-vascular endothelial growth factor therapy.
    Wilkins CS; Sobol EK; Lema GM; Lee JG; Rosen RB; Deobhakta A
    Eur J Ophthalmol; 2022 Sep; 32(5):NP37-NP41. PubMed ID: 33757333
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intravitreal Aflibercept injection with Panretinal photocoagulation versus early Vitrectomy for diabetic vitreous hemorrhage: randomized clinical trial.
    Abd Elhamid AH; Mohamed AAEA; Khattab AM
    BMC Ophthalmol; 2020 Apr; 20(1):130. PubMed ID: 32252674
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Off-label uses of Aflibercept, Ranibizumab and Dexamethasone implant for diabetic retinopathy in Turkey.
    Yilmaz M; Citirik M; Rahmanlar H; Alkan A; Gursoz H
    Rom J Ophthalmol; 2022; 66(4):304-309. PubMed ID: 36589330
    [No Abstract]   [Full Text] [Related]  

  • 34. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR PROLIFERATIVE DIABETIC RETINOPATHY: A Systematic Review and Meta-Analysis.
    Simunovic MP; Maberley DA
    Retina; 2015 Oct; 35(10):1931-42. PubMed ID: 26398553
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial.
    Sivaprasad S; Prevost AT; Vasconcelos JC; Riddell A; Murphy C; Kelly J; Bainbridge J; Tudor-Edwards R; Hopkins D; Hykin P;
    Lancet; 2017 Jun; 389(10085):2193-2203. PubMed ID: 28494920
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and Outcomes of Intravitreal Aflibercept in Diabetic Macular Edema - A Systematic Review.
    Dascalu AM; Rizzo M; Rizvi AA; Stoian AP; Iancu RC; Stana D; Tudosie MS; Serban D
    Curr Pharm Des; 2022; 28(21):1758-1768. PubMed ID: 35469564
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab.
    Bressler SB; Liu D; Glassman AR; Blodi BA; Castellarin AA; Jampol LM; Kaufman PL; Melia M; Singh H; Wells JA;
    JAMA Ophthalmol; 2017 Jun; 135(6):558-568. PubMed ID: 28448655
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevention of vision-threatening complications in diabetic retinopathy: two perspectives based on results from the DRCR Retina Network Protocol W and the Regeneron-sponsored PANORAMA.
    Nanegrungsunk O; Bressler NM
    Curr Opin Ophthalmol; 2021 Nov; 32(6):590-598. PubMed ID: 34419979
    [TBL] [Abstract][Full Text] [Related]  

  • 39. One-year real-life results on effect of intravitreal aflibercept in patients with diabetic macular oedema switched from ranibizumab.
    Lukic M; Williams G; Shalchi Z; Patel PJ; Hykin PG; Hamilton RD; Rajendram R
    Eur J Ophthalmol; 2021 May; 31(3):1171-1176. PubMed ID: 32452251
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intravitreal Bevacizumab in Diabetic Retinopathy. Recommendations from the Pan-American Collaborative Retina Study Group (PACORES): The 2016 Knobloch Lecture.
    Arevalo JF; Liu TYA;
    Asia Pac J Ophthalmol (Phila); 2018; 7(1):36-39. PubMed ID: 29280367
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.